Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Carla M Nester, MD, MSA, FASN
University of Iowa Stead Family Children's Hospital
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Investigative Site
Poitiers, France
- Investigative Site
Toulouse, France
- Investigative Site
Bari, Italy
- Investigative Site
Bergamo, Italy
- Investigative Site
Brescia, Italy
- Investigative Site
Turin, Italy
- Investigative Site #1
Barcelona, Spain
- Investigative Site #2
Barcelona, Spain
- Investigative Site #1
Madrid, Spain
- Investigative Site #2
Madrid, Spain
- Investigative Site
Oxford, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Feb 2022
- Primary completion
- 23 Sept 2022
- Completion
- 23 Sept 2022
- Last update posted
- 2 May 2024
- Registered enrollment
- 2
- Registry id
- NCT05162066
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.